• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer

    12/16/24 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email

    Wendy Barnes, Current CEO of RxBenefits, Brings Extensive Healthcare Management Experience to the Company

    GoodRx Holdings, Inc. (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216730604/en/

    Wendy Barnes (Photo: Business Wire)

    Wendy Barnes (Photo: Business Wire)

    Wendy will join GoodRx following her role as CEO of RxBenefits, where she led the company in providing pharmacy benefit support to more than 2,000 self-insured clients comprised of more than three million lives. Under her guidance, RxBenefits became a leading entity providing tailored pharmacy benefit solutions that promote affordability and transparency. Before that, as President of Express Scripts Pharmacy, Wendy oversaw the service, operation, and financial success of the organization's multiple pharmacies on behalf of 100 million members. Wendy also served as Group Vice President at Rite Aid, where she was responsible for all aspects of managed care, including contracting, enhancing relationships with managed care organizations, overseeing pharmacy benefit managers and third-party payers, and developing strategic partnerships.

    "Wendy is joining GoodRx at a pivotal moment – both for the healthcare industry and for GoodRx. In a world where conventional insurance coverage is increasingly restrictive, and patients and healthcare professionals are bearing increasing costs and time burdens, GoodRx offers a complement to insurance that fills the gaps that existing systems don't cover and helps Americans save both time and money," said Scott Wagner, Interim CEO at GoodRx. "Wendy has the expertise, vision, and leadership to help GoodRx grow in unique and valuable ways, both for our customers and as a business. I'm excited for Wendy and I'm particularly excited for GoodRx."

    Wendy's career highlights include her effective leadership roles at RxBenefits, Express Scripts, Rite Aid and Pfizer, leading extensive pharmacy operations and simplifying and improving patient healthcare experiences. Wendy also served for 10 years as a Medical Service Corps Officer in the United States Air Force.

    "I am thrilled to join GoodRx and contribute to its mission of making healthcare more affordable for millions of Americans," said Wendy Barnes, the newly appointed President and CEO of GoodRx. "With the evolving challenges in healthcare delivery and management, I look forward to working with our talented executive leadership team to foster growth and innovation at GoodRx and within the industry. We have a tremendous opportunity to free Americans from friction in getting medication."

    In her role as CEO, Wendy will focus on advancing GoodRx's strategic initiatives, with particular attention on bringing all brand affordability programs onto the GoodRx platform, expanding GoodRx's product experience with healthcare professionals, and enriching partnerships with retail pharmacies, insurers, and pharmaceutical manufacturers to help save Americans time and money. Driven by a steadfast commitment to making healthcare more accessible and affordable, Wendy aims to build a better patient experience and help fill gaps within the existing system.

    "As we embark on this transition, I want to thank Scott for his hard work and huge impact over the last year and a half as our Interim CEO. His leadership and deep business expertise has been felt both inside and outside the walls of GoodRx," said Trevor Bezdek, Co-founder and Chairman of GoodRx. "As we look ahead to the next phase of growth, I'm confident and enthusiastic that Wendy's experience and dedication to improving patient lives will drive GoodRx's mission forward."

    About GoodRx

    GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.

    GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the new CEO appointment and related benefits and values; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241216730604/en/

    Get the next $GDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    2/26/2024$8.00Outperform
    Leerink Partners
    More analyst ratings

    $GDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

      Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

      3/17/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

      Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

      2/5/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

      WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

      1/6/25 9:00:00 AM ET
      $GDRX
      $MAPS
      EDP Services
      Technology
      Computer Software: Prepackaged Software

    $GDRX
    Financials

    Live finance-specific insights

    See more
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports Fourth Quarter and Full Year 2024 Results

      Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

      2/27/25 6:05:00 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      12/4/23 4:35:10 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/30/23 4:41:35 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/17/23 7:08:30 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/15/25 10:57:58 AM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/14/25 4:04:49 PM ET
      $GDRX
      EDP Services
      Technology
    • SEC Form 10-Q filed by GoodRx Holdings Inc.

      10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

      5/7/25 4:50:11 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/14/24 12:29:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/13/24 4:30:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/12/24 4:02:41 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Nabiey Romin converted options into 4,804 shares and covered exercise/tax liability with 1,719 shares, increasing direct ownership by 3% to 118,091 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/15/25 5:46:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 8% to 115,006 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/8/25 6:16:12 PM ET
      $GDRX
      EDP Services
      Technology
    • Director Idea Men, Llc converted options into 7,000,000 shares and returned $29,400,000 worth of shares to the company (7,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/21/25 4:23:24 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GoodRx to Launch Direct Contracting for Independent Community Pharmacies

      GoodRx is hosting a webinar on June 3 and 4 to discuss how the company is supporting direct contracting with GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide independent pharmacies with more direct control over pricing and favorable margins. GoodRx is committed to helping independent

      5/22/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on GoodRx with a new price target

      Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

      12/4/24 7:38:07 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by Raymond James with a new price target

      Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

      8/9/24 7:30:17 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously

      5/23/24 7:39:11 AM ET
      $GDRX
      EDP Services
      Technology